Form 4: Aprea Therapeutics Director Boosts Stake in Private Placement

Aprea Therapeutics Director Marc Duey acquired 21,459 shares of common stock and an equal number of warrants in a private placement.

Summary

• Marc Duey, a Director of Aprea Therapeutics, Inc. (APRE), acquired securities on December 10, 2025.
• He purchased 21,459 shares of common stock at a price of $1.165 per share.
• He also received 21,459 common warrants with an exercise price of $1.04.
• This acquisition was part of a private placement entered into on December 8, 2025, with certain accredited investors, including the reporting person.
• Following the transaction, Marc Duey directly owns 256,155 shares of common stock and 21,459 common warrants.
• An additional 602 shares are indirectly owned by his spouse, for which he disclaims beneficial ownership.
• The common warrants are immediately exercisable but are subject to beneficial ownership limitations, preventing exercise if it would cause the holder's ownership to exceed 4.99% of outstanding common stock or 9.99% of combined voting power.
• The warrants will expire on the fifth-year anniversary of the earlier of the registration statement's effective date or the date shares are eligible for sale under Rule 144.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to a director's direct investment in the company's stock and warrants, signaling confidence. While a private placement can cause dilution, insider participation often offsets some of that concern.

Positives

• A Director, Marc Duey, increased his direct ownership in the company by acquiring 21,459 shares of common stock, signaling confidence in the company's future.
• The acquisition was part of a private placement, indicating a direct investment by an insider.
• The Director also received 21,459 common warrants, providing additional upside potential.

Negatives

• The private placement, while involving insider participation, can lead to dilution for existing shareholders.

Risks

• The common warrants are subject to beneficial ownership limitations, preventing exercise if it would cause the holder's ownership to exceed 4.99% of outstanding common stock or 9.99% of combined voting power.
• The common warrants have a defined expiration date (fifth-year anniversary of certain events), after which they become worthless if not exercised.

Future Outlook

No specific forward-looking statements or guidance from the company are provided in this Form 4, beyond the terms and conditions of the warrants.

Industry Context

This filing reports an insider transaction and a private placement. Insider buying can signal confidence in future prospects within any industry. Private placements are a common method for companies, particularly in sectors like biotech/pharma, to raise capital quickly from accredited investors.

Comparison to Industry Standards

• Insider buying, especially by a director, is generally viewed positively across industries as it signals confidence in the company's future performance.
• Private placements are a standard method for companies, particularly in the biotech sector, to raise capital quickly from accredited investors, often at a discount or with attached warrants, which is consistent with industry practice.
• The beneficial ownership limitations on warrant exercise (4.99% and 9.99%) are common provisions in private placement agreements to avoid triggering certain regulatory reporting requirements or change of control provisions.

Related Party Transactions

• The reporting person, Marc Duey, is a Director of Aprea Therapeutics, Inc.
• He participated in a private placement where he purchased shares and warrants directly from the Issuer.

Stakeholder Impact

• Shareholders: Potential dilution from the private placement, but also a positive signal from insider buying.
• Company: Successfully raised capital through a private placement.

Next Steps

• Potential exercise of the common warrants by the reporting person, subject to beneficial ownership limitations.
• The company may need to file a registration statement for the underlying shares of the common warrants for them to be freely tradable.

Key Dates

Recommendation

A director's decision to increase their stake through a private placement, acquiring both common stock and warrants, typically signals confidence in the company's future prospects. This insider buying can be a positive indicator for investors. However, without a broader financial analysis of Aprea Therapeutics' overall performance, strategic direction, and market conditions, a definitive 'buy' or 'sell' recommendation is premature. The private placement itself, while a capital raise, can also lead to some dilution. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor further developments and broader company fundamentals.

Keywords

Aprea Therapeutics, APRE, Marc Duey, Insider Buying, Form 4, Private Placement, Common Stock, Warrants, Director, Equity Acquisition